Literature DB >> 16835250

Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.

Ghazaleh Tabatabai1, Brigitte Frank, Robert Möhle, Michael Weller, Wolfgang Wick.   

Abstract

Previously we defined a pathway of transforming growth factor beta (TGF-beta) and stromal cell-derived factor-1/CXC chemokine ligand 12 (SDF-1alpha/CXCL12) dependent migration of adult haematopoietic stem and progenitor cells (HPC) towards glioma cells in vitro and their homing to experimental gliomas in vivo. Hypoxia is a critical aspect of the microenvironment of gliomas and irradiation is an essential part of the standard therapy. To evaluate the therapeutic potential of HPC as vectors for a cell-based therapy of gliomas, we investigated the impact of hypoxia and irradiation on the attraction of HPC by glioma cells. Temozolomide (TMZ) treatment and hyperthermia served as controls. Supernatants of irradiated or hypoxic LNT-229 glioma cells promote HPC migration in vitro. Reporter assays reveal that the CXCL12 promoter activity is enhanced in LNT-229 cells at 24 h after irradiation at 8 Gy or after exposure to 1% oxygen for 12 h. The irradiation- and hypoxia-induced release of CXCL12 depends on hypoxia inducible factor-1 alpha (HIF-1alpha), but not on p53. Induction of transcriptional activity of HIF-1alpha by hypoxia or irradiation requires an intact TGF-beta signalling cascade. This delineates a novel stress signalling cascade in glioma cells involving TGF-beta, HIF-1alpha and CXCL12. Stress stimuli can be irradiation, hypoxia or TMZ, but not hyperthermia. Cerebral irradiation of nude mice at 21 days after intracerebral implantation of LNT-229 glioma induces tumour satellite formation and enhances the glioma tropism of HPC to the tumour bulk and even to these satellites in vivo. These data suggest that the use of HPC as cellular vectors in the treatment of glioblastoma may well be combined with irradiation or other anti-angiogenic therapies that induce tumour hypoxia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16835250     DOI: 10.1093/brain/awl173

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  48 in total

Review 1.  Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology.

Authors:  Meizhang Li; Richard M Ransohoff
Journal:  Prog Neurobiol       Date:  2007-11-26       Impact factor: 11.685

Review 2.  K+ channel signaling in irradiated tumor cells.

Authors:  Benjamin Stegen; Lukas Klumpp; Milan Misovic; Lena Edalat; Marita Eckert; Dominik Klumpp; Peter Ruth; Stephan M Huber
Journal:  Eur Biophys J       Date:  2016-05-10       Impact factor: 1.733

3.  Endothelial progenitor cell transplantation improves long-term stroke outcome in mice.

Authors:  Yongfeng Fan; Fanxia Shen; Tim Frenzel; Wei Zhu; Jianqin Ye; Jianrong Liu; Yongmei Chen; Hua Su; William L Young; Guo-Yuan Yang
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

4.  Aging attenuates radiation-induced expression of pro-inflammatory mediators in rat brain.

Authors:  Won Hee Lee; William E Sonntag; Yong Woo Lee
Journal:  Neurosci Lett       Date:  2010-04-10       Impact factor: 3.046

Review 5.  CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

Authors:  Dan G Duda; Sergey V Kozin; Nathaniel D Kirkpatrick; Lei Xu; Dai Fukumura; Rakesh K Jain
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

6.  Developing Implantable Scaffolds to Enhance Neural Stem Cell Therapy for Post-Operative Glioblastoma.

Authors:  Kevin T Sheets; Matthew G Ewend; Mahsa Mohiti-Asli; Stephen A Tuin; Elizabeth G Loboa; Karen S Aboody; Shawn D Hingtgen
Journal:  Mol Ther       Date:  2020-02-13       Impact factor: 11.454

7.  Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.

Authors:  Sally K Martin; Peter Diamond; Sharon A Williams; Luen Bik To; Daniel J Peet; Nobutaka Fujii; Stan Gronthos; Adrian L Harris; Andrew C W Zannettino
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

Review 8.  Hypoxic tumor microenvironment and cancer cell differentiation.

Authors:  Yuri Kim; Qun Lin; Peter M Glazer; Zhong Yun
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

9.  Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.

Authors:  J E Bohonowych; U Gopal; J S Isaacs
Journal:  J Oncol       Date:  2010-06-24       Impact factor: 4.375

Review 10.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.